News

Exciting Phase 2 Results from Actuate's Elraglusib in Cancer Treatment

Exciting Phase 2 Results from Actuate's Elraglusib in Cancer Treatment

Actuate Therapeutics Unveils Promising Findings at ASCO

Actuate Therapeutics, Inc. (NASDAQ: ACTU) has shared groundbreaking topline results from its Phase 2 trial, known as Actuate-1801 Part 3B, which explores the use of elraglusib in treating patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). These results indicate a significant improvement in survival for previously untreated patients, providing hope in an area where effective treatments are desperately needed.

Innovative Treatment Approaches

The Phase 2 trial focused on patients receiving elraglusib combined with gemcitabine/nab-paclitaxel (GnP). The findings revealed a statistically significant enhancement in both median overall survival and the one-year survival rate when compared to those treated with GnP alone. This is a major milestone for the treatment landscape of pancreatic cancer, highlighting the potential of novel therapies.

Key Presentation Details

The oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for late May, will further illuminate these findings. Leading the presentation is Dr. Devalingam Mahalingam from Northwestern University Feinberg School of Medicine, who will explain how the elraglusib/GnP combination therapy demonstrated consistent improvements across all primary efficacy measures. This presentation promises to share insights that could reshape treatment protocols for mPDAC patients.

Significance of the Findings

Daniel Schmitt, President & Chief Executive Officer of Actuate, commented on the study’s results, stressing the unyielding poor prognosis historically faced by metastatic PDAC patients. Achieving statistical significance in survival rates through a Phase 2 study of this caliber is a remarkable feat. Schmitt underscored that the elraglusib data is more compelling with every new analysis, suggesting its emergence as a leading candidate in treating this challenging cancer. The positive outlook on elraglusib may well lead to substantial opportunities for further investment and research.

Upcoming Events to Discuss the Findings

To dive deeper into the study results, Actuate plans to host a Key Opinion Leader (KOL) event right after the ASCO presentation. This event aims to engage the investment community and discuss the data in great detail. The session will feature a panel of experts, moderated by Schmitt, including notable figures from esteemed medical institutions.

Understanding elraglusib

Elraglusib is a GSK-3? inhibitor that has shown potential in fostering anti-tumor immunity while enhancing the efficacy of existing chemotherapy regimens. Research indicates that manipulating molecular pathways involved in tumor growth can yield better patient outcomes. Participants in the Phase 2 trial were randomized to receive either elraglusib with GnP or just GnP. The specific aim was to evaluate the impact on various survival and response measures, including overall survival and disease control rates.

A Closer Look at GSK-3? Inhibition

Inhibition of GSK-3? may not only help in adverse tumor growth conditions but also potentially regulate gene expressions tied to tumor metabolism. This dual action may lead to improved treatment responses and survival in patients suffering from aggressive cancers. Actuate's commitment to studying this area reflects a promising avenue for cancer therapeutics.

About Actuate Therapeutics, Inc.

Actuate Therapeutics is a forward-thinking biopharmaceutical company dedicated to developing innovative therapies for challenging cancers. With elraglusib at the forefront, Actuate targets crucial cancer pathways often responsible for resistance to treatment. The company harnesses the potential of this novel drug to manipulate immune responses and enhance the effectiveness of chemotherapy, presenting a compelling future for cancer treatment.

Frequently Asked Questions

What are the main findings of the Actuate-1801 trial?

The trial demonstrated that elraglusib in combination with GnP significantly improved overall survival and 1-year survival rates in patients with metastatic pancreatic cancer.

How does elraglusib work?

Elraglusib functions as a GSK-3? inhibitor, impacting multiple pathways associated with tumor growth and aiding in anti-tumor immune responses.

What is the significance of the ASCO presentation?

The ASCO presentation will share crucial data supporting elraglusib's effectiveness, offering insights into its potential to transform treatment for metastatic pancreatic cancer.

Who will be presenting the findings at ASCO?

Dr. Devalingam Mahalingam from Northwestern University Feinberg School of Medicine will present the key findings during the meeting.

How can investors catch the KOL event?

Actuate will host the KOL event on May 31, 2025, featuring discussions on the latest data from the trial, specifically aimed at the investment community.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Stowers Brings a Transformation CTO Into Its Lab

Updated Category News Views 125

Data Has Become Lab Infrastructure Microscopes may get the glory, but the plumbing behind modern biology is increasingly digital, sprawling and unforgiving. That is why Stowers Institute for Medical Research appointing Brandon Mayer as vice president and chief technology officer on November 19, 2026, deserves more attention than the usual executive-shuffle treatment. This...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 20

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 118

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 83

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 58

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 135

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
Epilepsy Campaign Puts Patient Voices Before Investors

Updated Category News Views 0

An epilepsy diagnosis can turn ordinary family routines into a maze overnight, which is why awareness work deserves more than the usual polite nod and a colored ribbon. Mediaplanet's national Epilepsy Awareness campaign, launched November 20, 2026, brings the subject into a USA TODAY print insert and related digital coverage during Epilepsy Awareness Month. That reach...

Continue Reading
L’Oréal’s Women of Worth Shows Why Brand Patience Matters

Updated Category News Views 138

Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...

Continue Reading

Top 5 Most Recently Viewed Articles

MAGNA-TILES Unveils Exciting Rail Racers To Transform Play

Updated Category News Views 562

MAGNA-TILES Innovates Play with Rail Racers Launch First Fan-Made Invention Reimagines Ball Runs and Takes Magnetic Building to the Next Level MAGNA-TILES, America’s favorite magnetic building toy brand, has introduced an exciting innovation—the Rail Racers. This remarkable new product debuted at the American International Toy Fair, showcasing the creativity of the...

Continue Reading
Discover DDB Miner’s Innovative Approach to Bitcoin Mining

Updated Category News Views 167

Unlocking the Future of Bitcoin Mining DDB Miner, a forward-thinking Bitcoin mining entity, is making significant strides in the cryptocurrency industry. By emphasizing low-cost and efficient operations, DDB Miner is set on a path to redefine how Bitcoin is mined. Their latest operational update sheds light on impressive developments and ambitious plans that promise to...

Continue Reading
Warren Buffett Plans Charitable Giving with New CEO Transition

Updated Category News Views 217

Warren Buffett Speeds Up Charitable Contributions Warren Buffett recently announced that he will accelerate the distribution of his vast fortune, amounting to $149 billion, to his children's charitable foundations. This strategic decision aligns with the responsibilities he feels as a father, recognizing the increasing ages of his children. The Transition to Greg Abel As...

Continue Reading
Understanding the DeFi Technologies Class Action and Its Impact

Updated Category News Views 238

DeFi Technologies Class Action Explained Robbins LLP recently brought to light a class action lawsuit on behalf of investors who bought or acquired shares of DeFi Technologies Inc. (NASDAQ: DEFT). This action covers a specific timeframe, reflecting concerns over the company’s alleged misrepresentation of its business prospects. Investors seeking clarity on this...

Continue Reading
Alibaba's Robotics Innovation: Shaping the Future of AI Tech

Updated Category News Views 199

Alibaba's Bold Move into Robotics Alibaba Group (NYSE: BABA) has embarked on an exciting new venture by launching its own robotics team to compete in the rapidly advancing field of AI-powered physical products. This initiative reflects Alibaba's commitment to integrating artificial intelligence into everyday applications, transforming how technology interacts with the...

Continue Reading